Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HL301 for Radiation Pneumonitis in Unresectable NSCLC
NCT04632342Phase 2Unknown
- Sponsor
- Hanlim Pharm
- Start
- Nov 2020
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HL301 in radiation pneumonitis (RP), sponsored by Hanlim Pharm. Status: unknown.
02
Drugs
HL301
03
Conditions
radiation pneumonitis (RP)
Beyond the preview
Go deeper on NCT04632342.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04632342.